Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
← catalyst calendarSponsored by Vir Biotechnology, Inc. (industry) · VIR — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
244actual
Sites
37
Countries
Canada, Germany, Hong Kong +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-11 | actual | When the study began enrolling |
| Primary completion | 2026-03-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-16 | actual | The whole study's end, after follow-up |
| First posted | 2021-04-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatitis B, Chronic
Interventions
- Drug: VIR-2218 — also filed as Elebsiran
- Drug: VIR-3434 — also filed as Tobevibart
- Drug: PEG-IFNα
Primary outcomes
what the primary-completion date above is the date OFProportion of participants with treatment-emergent adverse events (TEAEs)
measured Up to 72 weeks
Proportion of participants with serious adverse events (SAEs)
measured Up to 72 weeks
Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatment
measured Up to 48 weeks
Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatment
measured Up to 72 weeks
Publications
- PMID 41586499 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · VIR's whole pipeline · Catalyst calendar · Every registered study · What changed